Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus.

Current Opinion in HIV and AIDS
Mohube B MaepaPatrick Arbuthnot

Abstract

The available vaccine and therapies against hepatitis B virus (HBV) rarely eliminate chronic infection with the virus. High mortality resulting from complicating cirrhosis and hepatocellular carcinoma makes improving anti-HBV therapy an important priority. Recent advances with using gene therapy to counter HBV have potential and are the focus of this review. The stable replication-competent HBV intermediate comprising covalently closed circular DNA (cccDNA) is the template for expression of all viral genes. Inactivating cccDNA has thus been a focus of research aimed at achieving cure for HBV infection. Many studies have reported profound inhibition of replication of the virus using silencing and editing techniques. Therapeutic gene silencing with synthetic short interfering RNA is now in clinical trials. Ability to mutate and permanently inactivate cccDNA with engineered gene editors, such as those derived from CRISPR/Cas or TALENs, is particularly appealing but has not yet reached clinical evaluation. Gene silencing and gene editing potentially provide the means to cure HBV infection. However, achieving efficient delivery of therapeutic sequences, ensuring their specificity of action and progress with other antiviral strategie...Continue Reading

References

Oct 2, 2003·Genome Biology·Raul Urrutia
Mar 21, 2007·Nature Medicine·Federico MingozziKatherine A High
Nov 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Andreas SchulzeStephan Urban
Jan 13, 2009·The Journal of Infectious Diseases·Roberto CalcedoJames M Wilson
Feb 18, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Thomas J CradickAnton P McCaffrey
Jul 19, 2012·Biochemistry. Biokhimii︠a︡·S V RazinO L Kantidze
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Jul 26, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kristie BloomPatrick Arbuthnot
Sep 13, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jieliang ChenZhenghong Yuan
Aug 19, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Florian van BömmelAnke Edelmann
Aug 20, 2014·Molecular Therapy. Nucleic Acids·Su-Ru LinPei-Jer Chen
Sep 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Christian KönigerMichael Nassal
Dec 17, 2014·Molecular Therapy. Nucleic Acids·Christoph Seeger, Ji A Sohn
Sep 4, 2015·Scientific Reports·Madina KarimovaJoachim Hauber
Dec 15, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maximilian MüllerClaudio Mussolino
Nov 9, 2016·Journal of Hepatology·Katja GierschMarc Lütgehetmann
Dec 20, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Danny Ka-Ho WongMan-Fung Yuen
Dec 25, 2016·American Journal of Physiology. Lung Cellular and Molecular Physiology·Juan SongMachteld N Hylkema
Jan 4, 2017·Hepatoma Research·R Jason LamontagneMichael J Bouchard
Feb 19, 2017·BMC Genomics·Francesca GuerrieriMassimo Levrero
Feb 22, 2017·Nature Communications·Eunji KimJin-Soo Kim
Apr 22, 2017·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Aug 2, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S LokMarc G Ghany
Oct 23, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nicole K PaulkMark A Kay
Nov 22, 2017·Digestive Diseases and Sciences·Jingwu DongMiaomiao Zhang

❮ Previous
Next ❯

Citations

Aug 27, 2021·The Journal of Physical Chemistry. B·Sudipta SenapatiPralay Maiti

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Related Papers

Advances in Experimental Medicine and Biology
Kristie BloomPatrick Arbuthnot
Molecular Therapy : the Journal of the American Society of Gene Therapy
Abdullah ElyPatrick Arbuthnot
© 2021 Meta ULC. All rights reserved